IRLAB to Advance Clinical Development of IRL790 in LIDs Based on In-depth Analysis of Positive Phase IIa Results

By In The News
August 28, 2019 in The Headlines

Recommended Posts

In The News

Posted August 28, 2019

- Share

Posted August 28, 2019

STOCKHOLM, Aug. 28, 2019 /PRNewswire/ -- IRLAB (Nasdaq First North Premier: IRLAB A) today announced that the in-depth analysis of the data from the recently concluded Phase IIa study of IRL790 in Parkinson's patients with L-dopa induced dyskinesia (LIDs) brings further evidence of the...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  219920
2. Jaydee
  16805
3. Kip Powick
  12216
4. deicer
  12196
5. dagger
  9595
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  270.2k
- Total Posts
  
  558.8k

Sign In

IRLAB to Advance Clinical Development of IRL790 in LIDs Based on In-depth Analysis of Positive Phase IIa Results

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support